Fort Washington Investment Advisors Inc. OH Has $35.65 Million Stake in Progyny, Inc. $PGNY

Fort Washington Investment Advisors Inc. OH lifted its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 33.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,656,558 shares of the company’s stock after purchasing an additional 412,395 shares during the period. Fort Washington Investment Advisors Inc. OH owned 1.93% of Progyny worth $35,649,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in Progyny in the 3rd quarter valued at $583,000. Exchange Traded Concepts LLC bought a new stake in shares of Progyny in the third quarter valued at about $803,000. USA Financial Formulas acquired a new position in shares of Progyny in the third quarter valued at about $100,000. Voya Investment Management LLC grew its stake in shares of Progyny by 9.5% in the third quarter. Voya Investment Management LLC now owns 236,833 shares of the company’s stock valued at $5,097,000 after acquiring an additional 20,498 shares in the last quarter. Finally, State of Wyoming increased its position in Progyny by 368.8% during the second quarter. State of Wyoming now owns 22,793 shares of the company’s stock worth $501,000 after acquiring an additional 17,931 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent research reports. Barclays assumed coverage on shares of Progyny in a report on Monday, December 8th. They issued an “overweight” rating and a $29.00 price objective for the company. Canaccord Genuity Group lifted their price target on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research report on Monday, December 22nd. KeyCorp upgraded Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective on the stock in a research note on Tuesday, November 11th. Finally, Wall Street Zen cut Progyny from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Progyny Trading Down 0.7%

Shares of Progyny stock opened at $25.62 on Tuesday. The company has a market cap of $2.21 billion, a PE ratio of 40.67, a price-to-earnings-growth ratio of 2.03 and a beta of 0.96. The company has a 50 day moving average of $23.75 and a 200-day moving average of $22.74. Progyny, Inc. has a 1-year low of $16.20 and a 1-year high of $27.76.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.06. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business had revenue of $313.35 million for the quarter, compared to analysts’ expectations of $299.23 million. During the same period last year, the firm posted $0.11 earnings per share. The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Research analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Mark S. Livingston sold 21,303 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the sale, the chief financial officer directly owned 48,358 shares in the company, valued at $1,233,129. This represents a 30.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter Anevski acquired 79,500 shares of Progyny stock in a transaction that occurred on Thursday, November 13th. The stock was acquired at an average cost of $24.29 per share, for a total transaction of $1,931,055.00. Following the completion of the purchase, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at $16,523,296.79. This represents a 13.23% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold a total of 22,046 shares of company stock valued at $561,691 in the last three months. 9.40% of the stock is owned by insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.